Drug Trial Radar · NCT01371630
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
276
Planned (sponsor's estimate)
Start
Aug 26, 2011
Primary completion
Dec 25, 2027
Study completion Dec 25, 2027
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 13, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Burkitt-Like Lymphoma With 11q Aberration
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Burkitt Lymphoma
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Burkitt Lymphoma
Interventions
BlinatumomabBiological
Given CIVI
CyclophosphamideDrug
Given IV
CytarabineDrug
Given IT and IV
DexamethasoneDrug
Given IV or PO
Inotuzumab OzogamicinBiological
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
MercaptopurineDrug
Given PO
MethotrexateDrug
Given IT, IV, and PO
PrednisoneDrug
Given PO
RituximabBiological
Given IV
VincristineDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose of inotuzumab ozogamicin based on incidence of dose limiting toxicities (Phase I)Time frame: 28 days
- Progression free survival (PFS) in frontline elderly acute lymphoblastic leukemia (ALL) (Phase II)Time frame: 2 years
- Response rate in refractory-relapsed acute lymphoblastic leukemia (ALL) (Phase II)Time frame: Up to 5 years
- Survival in refractory-relapsed acute lymphoblastic leukemia (ALL) (Phase II)Time frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.